News

Robotic Ribosome
Enlarge image

ResearchUK

Robotic Ribosome

11.01.2013 - Researches have constructed the first molecular machine that can produce peptides of defined sequences in milligram quantities.

The group of Bartosz Lewandowski from University of Manchester have taken another step toward the creation of a synthetic machine that performs the duties of a ribosome, which builds proteins in living organisms by joining amino acids together. As reported in Science, they have designed an artificial small-molecule machine that travels along a molecular strand, picking up amino acids that block its path, to synthesise a peptide in a sequence-specific manner.

The chemical structure is based on a rotaxane, a molecular ring threaded onto a molecular axle. The ring carries a thiolate group that iteratively removes amino acids in order from the strand and transfers them to a peptide-elongation site through native chemical ligation. The synthesis was demonstrated with ~1018 molecular machines acting in parallel; this process generated milligram quantities of a peptide with a single sequence confirmed by tandem mass spectrometry.

The study demonstrates that, in principle, small artificial molecular machines can be designed to perform such tasks autonomously. However, their machine lacked performance. In the current lab setting it only joined 3 amino acids together.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/robotic-ribosome.html

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.2%
  • VITA 344.32 EUR8.0%
  • BB BIOTECH157.70 EUR7.3%

FLOP

  • PAION2.24 EUR-30.0%
  • CYTOS0.16 CHF-27.3%
  • MAGFORCE5.90 EUR-17.5%

TOP

  • SANTHERA85.50 CHF2335.9%
  • CO.DON2.75 EUR192.6%
  • PAION2.24 EUR163.5%

FLOP

  • CYTOS0.16 CHF-95.8%
  • THERAMETRICS0.08 CHF-42.9%
  • 4SC0.97 EUR-42.6%

No liability assumed, Date: 23.10.2014